Information Provided By: 
Fly News Breaks for August 24, 2015
SRPT
Aug 24, 2015 | 06:50 EDT
Piper Jaffray upgraded Sarepta (SRPT) to Overweight and increased its price target to $48 from $28. The firm expects the FDA to accept the NDA filing eteplirsen for Duchenne Muscular Dystrophy, or DMD, when the 60-day review period expires tomorrow. Piper believes Sarepta met all of the FDA's requests for information and anticipates a joint AdCom for eteplirsen and BioMarin's (BMRN) drisapersen. The firm upgraded shares ahead of the regulatory proceeding and now values eteplirsen at $1.3B, up from $919M previously.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
